[LGM inferior vena cava filters--observation of 79 patients].
The aim of the study was to assess effectiveness and safety of the LGM inferior vena cava (IVC) filters in patients with venous thromboembolic disease. In the Department of Internal Medicine of Institute of Tuberculosis and Lung Diseases in Warsaw 79 LGM IVC filters have been inserted since 1993. Indications for filters placement were as follows: recurrent pulmonary embolism (pe) despite anticoagulation--17 patients (pts), severe bleeding complications of thrombolytic or anticoagulant therapy--11 pts, contraindications for thrombolytic and/or anticoagulant treatment--5 pts, massive pe--14 pts, chronic thromboembolic-major vessel pulmonary hypertension (CTEPH)--30 pts, extensive deep vein thrombosis of lower limbs or vena cava inferior in patients with urgent indications for surgery--24 pts. Each filter placement was preceded by cavography. The diagnostic procedures (mainly ultrasonography) were performed after 3-6 and 12 months in the first year then once yearly during follow-up period. Oral anticoagulants (OA) or low-molecular-weight heparins (LMWH) were instituted in the majority of patients. 58 patients are still alive, 21 patients died. Only two non-fatal episodes of recurrent pe were documented. Other complications were rare and insignificant. We have not observed excess rate of recurrent deep venous thrombosis nor thrombosis at the filter site. The LGM IVC filters are effective and safe in such selectively chosen group of patients.
Hajduk
B
B
Klinika Chorób Wewnetrznych Klatki Piersiowej Instytutu Gruźlicy i Chorób Płuc w Warszawie.
Tomkowski
W
W
Fijałkowska
A
A
Oniszh
K
K
Małek
G
G
Wawrzyńska
L
L
Radomyski
A
A
Filipecki
S
S
Torbicki
A
A
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage; D000075202:Contraindications; D005260:Female; D005500:Follow-Up Studies; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000209:etiology / Q000517:prevention & control*; D012008:Recurrence; D013924:Thrombophlebitis / Q000150:complications / Q000628:therapy*; D016306:Vena Cava Filters
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight